Substantial immune activation taking place post-Clevegen administration UK CTA approval
Share Talk Bulletin Board Heroes, Wednesday 5th December 2018
A charting look at some of the most followed stocks on the London market, Zak Mir covers.
Faron Pharma. Oy (LON:FARN) Patient subgroup identified from INTEREST trial
Dr Markku Jalkanen, CEO of Faron, said: “We have, and are continuing to build, a solid body of evidence which indicates that there is clearly a subgroup of patients for
Faron Pharmaceuticals Ltd (LON: FARN) Notice of Interim Results
TURKU – FINLAND, 8 August 2018 – Faron Pharmaceuticals Ltd (“Faron”) (AIM: FARN), the clinical stage biopharmaceutical company, will be announcing its interim results for the six months ended 30
